Mammaglobin-based strategies for treatment of breast cancer

Current Cancer Drug Targets

Volumn 4, Issue 6, 2004, Pages 531-542

  Goedegebuure, Peter S ^a   Watson, Mark A ^a   Viehl, Garsten T ^a   Fleming, Timothy P ^a  

^a USA   (United States)

Author keywords

Antibody; Apoptosis; Breast cancer; Diagnosis; Mammaglobin; T lymphocyte; Therapy; Vaccine

Indexed keywords

BCG VACCINE; CANCER VACCINE; CORYNEBACTERIUM PARVUM EXTRACT; IBRITUMOMAB TIUXETAN; INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAMMAGLOBIN; PEPTIDE; PROTEOLIPID PROTEIN; RADIOISOTOPE; RITUXIMAB; TOSITUMOMAB I 131; TOXIN; TRASTUZUMAB;

ADIPOSE TISSUE; ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; APOPTOSIS; BAX GENE; BINDING AFFINITY; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; DIAGNOSTIC APPROACH ROUTE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG TARGETING; EVIDENCE BASED MEDICINE; GENE; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; ISOTOPE LABELING; NONHODGKIN LYMPHOMA; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN TARGETING; REVIEW; SECRETOGLOBIN GENE; STROMA; TISSUE SPECIFICITY; TUMOR IMMUNITY; VALIDATION PROCESS;

EID: 4644353121     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009043332862     Document Type: Review

References (71)

1. Watson, M. A.; Fleming, T. P. Mammaglobin, a Mammary-Specific Member Of The Uteroglobin Gene Family, is Overexpressed in Human Breast Cancer. Cancer Res. 1996, 56, 860-865.
2. Watson, M. A.; Dintzis, S.; Darrow, C. M.; Voss, L. E.; DiPersio, J.; Jensen, R.; Fleming, T. P. Mammaglobin Expression in Primary, Metastatic, and Occult Breast Cancer. Cancer Res. 1999, 59, 3028-3033.
3. Parker, M. G.; White, R.; Hurst, H.; Needham, M.; Tilly, R. Prostatic Steroid-Binding Protein. Isolation and Characterization of C3 Genes. J. Biol. Chem. 1983, 258, 12-15.
4. Westphal, U. In Monographs on Endocrinology: Prostatic Steroid Binding Protein. (Steroid-Protein Interactions II); Springer-Verlag Berlin, Heidelberg, 1986, 27, pp. 302-320.
5. Chamberlain, L.; Mpanias, O.; Wang, T. Isolation, Properties, And Androgen Regulation of a 20-Kilodalton Protein From Rat Ventral Prostate. Biochemistry 1983, 22, 3072-3077.
6. Miele, L.; Cordella-Miele, E.; Mantile, G.; Peri, A.; Mukherjee, A. Uteroglobin and Uteroglobin-Like Proteins: the Uteroglobin Family of Proteins. J. Endocrin. Invest. 1994, 17, 679-692.
7. Mantile, G.; Miele, L.; Cordella-Miele, E.; Singh, G. Human Clara Cell 10-kDa Protein is the Counterpart of Rabbit Uteroglobin. J. Biol. Chem. 1993, 268, 20343-20351.
8. Karn, A. C. The Mouse Salivary Androgen-Binding Protein (ABP) Alpha Subunit Closely Resembles Chain 1 of the Cal Allergen FeI dl. Biochem. Genet. 1994, 32, 271-277.
9. Klug, J.; Beier, H. M.; Bernard, A.; Chilton, B. S.; Fleming, T. P.; Lehrer, R. I.; Miele, L.; Pattabiraman, N.; Singh, G. Uteroglobin/Clara Cell 10-kDa Family Of Proteins: Nomenclature Committee Report. Ann. NY Acad. Sci. 2000, 923, 348-354.
10. Carter, D.; Douglass, J. F.; Cornellison, C. D.; Retter, M. W.; Johnson, J. C.; Bennington, A. A.; Fleming, T. P.; Reed, S. G.; Houghton, R. L.; Diamond, D. L.; Vedvick, T. S. Purification and Characterization of the Mammaglobin/Lipophilin B Complex, a Promising Diagnostic Marker for Breast Cancer. Biochemistry 2002, 41, 6714-6722.
11. Colpitts, T. L.; Billing-Medel, P.; Friedman, P.; Granados, E. N.; Hayden, M.; Hodges, S.; Menhart, N.; Roberts, L.; Russel, J.; Stroupe, S. D. Mammaglobin is Found in Breast Tissue as a Complex with BU101. Biochemistry 2001, 40, 11048-11059.
12. Chowdhury, B.; Mantile-Selvaggi, G.; Miele, L.; Cordella-Miele, E.; Zhang, Z.; Mukherjee, A. B. Lys 43 and Asp 46 in Alpha-Helix 3 of Uteroglobin Are Essential for Its Phospholipase A2 Inhibitory Activity. Biochem. Biophys. Res. Commun. 2002, 295, 877-883.
13. Kundu, G.; Mantile, G.; Miele, L.; Cordella-Miele, E.; Mukherjee, A. Recombinant Human Uteroglobin Suppresses Cellular Invasiveness Via A Novel Class of High-Affinity Cell Surface Binding Site. Proc. Natl. Acad. Sci. USA 1996, 93, 2915-2919.
14. Beier, H. M.; Maurer, R. R. Uteroglobin and Other Proteins in Rabbit Blastocyst Fluid after Development In Vivo and In Vitro. Cell Tissue Res. 1975, 159, 1-10.
15. Daniel, J. C. Discovery and Perspectives from the Blastokinin Era. Ann. N.Y. Acad. Sci. 2000, 923, 1-8.
16. Kundu, G. C.; Zhang, Z.; Mantile-Selvaggi, G.; Mandal, A., Yuan, C. J.; Mukherjee, A. B. Uteroglobin Binding Proteins: Regulation of Cellular Motility and Invasion in Normal and Cancer Cells. Ann. NY Acad. Sci. 2000, 923, 234-248.
17. Leygue, E.; Snell, L.; Dotzlaw, H.; Hole, K.; Troup, S.; Hiller-Hitchcock, T.; Murphy, L. C.; Watson, P. H. Mammaglobin, a Potential Marker of Breast Cancer Nodal Metastasis. J. Pathol. 1999, 189, 28-33.
18. Min, C. J.; Tafra, L.; Verbanac, K. M. Identification of Superior Markers for Polymerase Chain Reaction Detection of Breast Cancer Metastases in Sentinel Lymph Nodes. Cancer Res. 1998, 58, 4581-4584.
19. Ooka, M.; Tamaki, Y.; Sakita, I.; Fujiwara, Y.; Yamamoto, H.; Miyake, Y.; Sekimoto, M.; Ohue, M.; Sugita, Y.; Miyoshi, Y.; Ikeda, N.; Noguchi, S.; Monden, M. Bone Marrow Micrometastases Detected By RT/PCR For Mammaglobin Can Be an Alternative Prognostic Factor of Breast Cancer. Breast Cancer Res. Treat. 2001, 67, 169-175.
20. Nass, S. J.; Hahm, H. A.; Davidson, N. Breast Cancer Biology Blossoms in the Clinic. Nat. Med. 1998, 7, 761-762.
21. Fornier, M.; Risio, M.; Van Poznak, C.; Seidman, A. HER2 Testing and Correlation with Efficacy of Trastuzumab Therapy. Oncology 2002, 101. 340-348.
22. Leget, G. A.; Czuczman, M. S. Use of rituximab, the new FDA-Approved Antibody. Curr. Opin. Oncol. 1998, 10, 548-551.
23. Czuczman, M. S.; Grillo-Lopez, A. J.; White, C. A.; Saleh, M.; Gordon, L.; LoBuglio, A. F.; Jonas, C.; Klippenstein, D.; Dallaire, B.; Varns, C. Treatment of Patients with Low-Grade B-Cell Lymphoma with T the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy. J. Clin. Oncol. 1999, 77, 268-276.
24. Kinoshita, T.; Nagai, H.; Murate, T.; Saito, H. CD20-Negative Relapse in B-Cell Lymphoma after Treatment with Rituximab. J. Clin. Oncol. 1998, 16, 3916.
25. Svensson, H. P.; Kadow, J. F.; Vrudhula, V.; Wallace, P.; Senter, P. D. Monoclonal Antibody-Beta-Lactamase Conjugates for the Activation Of A Cephalosporin Mustard Prodrug. Bioconjug. Chem. 1992, 3, 176-181.
26. Slamon, D. J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J.; Norton, L. Use of Chemotherapy Plus a Monoclonal Antibody against Her2 for Metastatic Breast Cancer That Overexpress Her2. N. Engl. J. Med. 2001, 344. 783-792.
27. Jenner, E. An Inquiry unto the Causes and Effects of the Variolae Vaccinae, a Disease in Some of the Western Counties of England, Particularly Gloucestershire- and Known by the Name of the Cow Pox. London: Sampson and Low; 1798, 12.
28. Coley, W. B. The Treatment of Malignant Tumors by Repeated Inoculation of Erysipelas: with a Report of Ten Original Cases. Am. J. Med. Sci. 1893, 105, 487-511.
29. Ehrlich, P. Uber den jetzigen Stand der Karzinomforschung. Ned. Tijdschr. Geneeskd. 1909, 5, 273-290.
30. Thomas, L. in Cellular and Humoral Aspects of Hypersensitivity States; Lawrence, H. S., ed.; Hoeber: New York, 1959, pp. 529-532.
31. Burnet, F. M. Immunological Aspects of Malignant Disease. Lancet 1967, 1, 1171-1174.
32. Shankaran, V.; Ikeda, H.; Bruce, A. T.; White, J. M.; Swanson, P. E.; Old, L. J.; Schreiber, R. D. IFNγ and Lymphocytes Prevent Primary Tumour Development and Shape Tumour Immunogenicity. Nature 2001, 410, 1107-1111.
33. Van den Broek, M. E.; Kagi, D.; Ossendorp, F.; Toes, R.; Vamvakas, S.; Lutz, W. K.; Melief, C. J.; Zinkernagel, R. M.; Hengarter, H. Decreased Tumor Surveillance in Perforin-Deficient Mice. J. Exp. Med. 1996, 184, 1781-1790.
34. Street, S. E. A.; Hayakawa, Y.; Zhan, Y.; Lew, A. M.; MacGregor, D.; Jamieson, A. M.; Diefenbach, A.; Yagita, H.; Godfrey, D. I.; Smyth, M. J. Innate Immune Surveillance Of Spontaneous B Cell Lymphomas by Natural Killer Cells and γδ T Cells. J. Exp. Med. 2004, 199, 879-884.
35. Schreiber, R. D.; Old, L. J.; Hayday, A. C.; Smyth, M. J. A Cancer Immunosurveillance Controversy. Nat. Immunol. 2004, 5, 4-5.
36. Dunn, G. P.; Bruce, A. T.; Ikeda, H.; Old, L. J.; Schreiber, R. D. Cancer Immunoediting: from Immunosurveillance to Tumor Escape. Nat. Immunol. 2002, 3, 991-998.
37. Rosenberg, S. A. Progress in Human Tumour Immunology and Immunotherapy. Nature 2001, 411, 380-384.
38. Ferlazzo, G.; Munz, C. NK Cell Compartments and Their Activation by Dendritic Cells. J. Immunol. 2004, 772, 1333-1339.
39. Smyth, M. J.; Thia, K. Y. T.; Street, S. E. A.; Cretney, E.; Trapani, J. A.; Taniguchi, M.; Kawano, T.; Pelikan, S. B.; Crowe, N. Y.; Godfrey, D. I. Differential Tumor Surveillance by Natural Killer (NK) and NKT cells. J. Exp. Med. 2000, 797, 661-668.
40. Smyth, M. J.; Crowe, N. Y.; Hayakawa, Y.; Takeda, K.; Yagita, H.; Godfrey, D. I. NKT Cells - Conductors of Tumor Immunity? Curr. Opin. Immunol. 2002, 14, 165-171.
41. Banchereau, J.; Steinman, R. M. Dendritic cells and the control of immunity. Nature 1998, 392, 245-252.
42. Smyth, M. J.; Godfrey, D. I.; Trapani, J, A. A Fresh Look at Tumor Immunosurveillance and Immunotherapy Nat. Immunol. 2001, 2, 293-299.
43. Rosenberg, S. A. A New Era For Cancer Immunotherapy Based On The Genes That Encode Cancer Antigens. Immunity 1999, 70, 281-287.
44. Van der Merwe, P. A.; Davis, S. J. Molecular interactions mediating T cell antigen recognition. Ann. Rev. Immunol. 2003, 27, 659-684.
45. Rosenberg, S. A. Adoptive Immunotherapy for Cancer. Sci. Am. 1990, 262, 62-69.
46. Dighe, A. S.; Richards, E.; Old, L. J.; Schreiber, R. D. Enhanced in Vivo Growth And Resistance to Rejection of Tumor Cells Expressing Dominant Negative IFN Gamma Receptors. Immunity 1994, 1, 447-456.
47. Rosenberg, S. A. Development of Effective Immunotherapy for the Treatment of Patients with Cancer. J. Am. Coll. Surg. 2004, 198, 685-696.
48. Dudley, M. E.; Wunderlich, J. R.; Robbins, P. F.; Yang, J. C.; Hwu, P.; Schwartzentruber, D. J.; Topalian, S. L.; Sherry, R.; Restifo, N.; Hubicki, A. M.; Robinson, M. R.; Raffeld, M.; Duray, P.; Seipp, C. A.; Rogers-Freezer, L.; Morton, K. E.; Mavroukakis, S. A.; White, D. E.; Rosenberg, S. A. Cancer Regression and Autoimmunity in Patients after Clonal Repopulation with Antitumor Lymphocytes. Science 2002, 298, 850-854.
49. Berinstein, N. Overview of Therapeutic Vaccination Approaches for Cancer. Semin. Oncol 2003, 30, 1-8.
50. Tanaka, Y.; Dowdy, S. F.; Linehan, D. C.; Eberlein, T. J.; Goedegebuure, P. S. Induction of antigen-specific cytotoxic T lymphocytes by recombinant HIV TAT-fusion protein-pulsed human monocyte-derived dendritic cells. J. Immunol. 2003, 170, 1291-1298.
51. Schwarze, S. R.; Hruska, K. A.; Dowdy, S. F. Protein transduction: unrestricted delivery into all cells? Trends Cell Biol. 2000, 10, 290-295.
52. Wadia, J. S.; Dowdy, S. F. Protein Transduction Technology. Curr. Opin. Biotech. 2002, 13, 52-56.
53. Kim, D. T.; Mitchell, D. J.; Brockstedt, D. G.; Fong, L.; Nolan, G. P.; Fathman, C. G.; Engleman, E. G.; Rothbard, J. B. Introduction of Soluble Proteins into the MHC Class 1 Pathway by Conjugation to an HIV Tat Protein. J. Immunol. 1997, 159, 1666-1668.
54. Sakaguchi, S. Regulatory T Cells: Key Controllers of Immunologic Self-Tolerance. Cell 2000, 101, 455-458.
55. Shevach, E. M. Certified Professionals: CD4(+)CD25(+) Suppressor T Cells. J. Exp. Med. 2001, 193, F41-F46.
56. Read, S.; Malmstrom, V.; Powrie, F. Cytotoxic T Lymphocyte-Associated Antigen 4 Plays An Essential Role in the Function of CD25(+)CD4(+) Regulatory Cells That Control Intestinal Inflammation. J. Exp. Med. 2000, 192, 295-302.
57. Jonuleit, H.; Schmitt, E.; Stassen, M.; Tuettenberg, A.; Knop, J.; Enk, A. H. Identification and Functional Characterization of Human CD4(+)CD25(+) T Cells with Regulatory Properties Isolated from Peripheral Blood. J. Exp. Med. 2001, 193, 1285-1294.
58. Stephens, L. A.; Mottet, C.; Mason, D.; Powrie, F. Human CD4(+)CD25(+) Thymocytes and Peripheral T Cells Have Immune Suppressive Activity in Vitro. Eur. J. Immunol. 2001, 31, 1247-1254.
59. Piccirillo, C. A.; Shevach, E. M. Cutting edge: control of CD8+ T Cell Activation by CD4+CD25+ Immunoregulatory Cells. J. Immunol. 2001, 167, 1137-1140.
60. Azuma, T.; Takahashi, T.; Kunisato, A.; Kitamura, T.; Hirai, H. Human CD4+ CD25+ regulatory T cells suppress NKT cell functions. Cancer Res. 2003, 63, 4516-4520.
61. Shimizu, J.; Yamazaki, S.; Sakaguchi, S. Induction of Tumor Immunity by Removing CD25+CD4+ T Cells: a Common Basis between Tumor Immunity and Autoimmunity. J. Immunol 1999, 163, 5211-5218.
62. Sutmuller, R. P.; Van Duivenvoorde, L. M.; Van Elsas, A.; Schumacher, T. N.; Wildenberg, M. E.; Allison, J. P.; Toes, R. E.; Offringa, R.; Melief, C. J. Synergism of Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade and Depletion of CD25(+) Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses. J. Exp. Med. 2001, 194, 823-832.
63. Woo, E. Y.; Chu, C. S.; Goletz, T. J.; Schlienger, K.; Yeh, H.; Coukos, G.; Rubin, S. C.; Kaiser, L. R.; June, C. H. Regulatory CD4(+)CD25(+) T Cells in Tumors From Patients With Early-Stage Non-Small Cell Lung Cancer and Late-Stage Ovarian Cancer, Cancer Res. 2001, 61, 4766-4772.
64. Liyanage, U. K.; Moore, T. T.; Joo, H. G.; Tanaka, Y.; Herrmann, V.; Doherty, G.; Drebin, J. A.; Strasberg, S. M.; Eberlein, T. J.; Goedegebuure, P. S.; Linehan, D. C. Prevalence of Regulatory T Cells is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma. J. Immunol. 2002, 169, 2756-2761.
65. Tanaka, Y.; Amos, K.; Fleming, T. P.; Eberlein, T. J.; Goedegebuure, P. S. Mammaglobin-A is a Tumor-Associated Antigen in Human Breast Carcinoma. Surgery 2003, 133, 74-80.
66. Jaramillo, A.; Majumder, K.; Manna, P. P.; Fleming, T. P.; Doherty, G.; DiPersio, J. F.; Mohanakumar, T. Identification of HLA-A3-Restricted CD8+ T Cell Epitopes Derived From Mammaglobin-A, a Tumor-Associated Antigen of Human Breast Cancer. Int. J. Cancer 2002, 102, 499-506.
67. Narayanan, K.; Jaramillo, A., Benshoff, N. D.; Campbell, L. G.; Fleming, T. P.; Dietz. J. R.; Mohanakumar, T. Regresion of Established Human Breast Tumors Induced by Vaccination with Mammaglobin-A cDNA. J. Natl. Cancer Inst. 2004, in press.
68. Holt, L.; Rieser, C.; Papesh, C.; Ramoner, R.; Herold, M.; Klocker, H.; Radmayr, C.; Stenzl. A.; Bartsch, G.; Thurnher, M. Cellular and Humoral Immune Responses in Patients with Metastatic Renal Cell Carcinoma after Vaccination with Antigen Pulsed Dendritic Cells. J. Urol. 1999, 161, 777-782.
69. Morse, M. A.; Deng, Y.; Coleman, D.; Hull, S.; Kitrell-Fisher, E.; Nair, S.; Schlom, J.; Ryback, M. -E.; Lyerly, H. K. A Phase I Study of Active Immunotherapy with Carcinoembryonic Antigen Peptide (CAP-1)-Pulsed, Autologous Human Cultured Dendritic Cells in Patients with Metastatic Malignancies Expressing Carcinoembryonic Antigen. Clin. Cancer Res. 1999, 5, 1331-1338.
70. Lodge, P. A.; Jones, L. A.; Bader, R. A.; Murphy, G. P.; Salgaller, M. L. Dendritic Cell-Based Immunotherapy Of Prostate Cancer: Immune Monitoring of a Phase 11 Clinical Trial. Cancer Res. 2000, 60, 829-833.
71. Nestle, F. O.; Alijagic, S.; Gilliet, M.; Sun, Y.; Grabbe, S.; Dummer, R.; Burg, G.; Schadendorf, D. Vaccination of Melanoma Patients with Peptide- or Tumor Lysate-Pulsed Dendritic Cells. Nat. Med. 1998, 4, 328-332.